Trial Profile
Phase II Randomized Double Blind Trial of PF-04518600, an OX40 Antibody, in Combination With Axitinib Versus Axitinib in Immune-Checkpoint Inhibitor Exposed Patients With Metastatic Renal Cell Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Aug 2023
Price :
$35
*
At a glance
- Drugs Ivuxolimab (Primary) ; Axitinib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 09 Aug 2023 Planned End Date changed from 19 Jul 2024 to 19 Jul 2025.
- 09 Aug 2023 Planned primary completion date changed from 19 Jul 2023 to 19 Jul 2024.
- 05 Aug 2022 Planned End Date changed from 19 Jul 2023 to 19 Jul 2024.